Hamburg, Germany, 27 October 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced that the Company has received a payment of US$ 25 m from Bristol Myers Squibb (NYSE: BMY) for scientific progress achieved within their strategic neuroscience partnership. The payment will advance further research and the partners’ joint pipeline of programs aimed at tackling neurogenerative diseases.

Launched in 2016, the collaboration focuses on discovering and developing disease-modifying treatments for neurodegenerative diseases, where current treatment options remain limited. Since then, the companies have built a strong pipeline of innovative programs, including EVT8683, in-licensed by Bristol Myers Squibb in 2021 as BMS-986419, that has completed Phase 1 clinical trials. The partnership was extended in 2023 for an additional eight years, reflecting the shared commitment to bringing transformative treatments into the clinic.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Patients living with neurodegenerative conditions urgently need therapies that go beyond the management of symptoms. This achievement increases the depth of our collaboration with Bristol Myers Squibb. Together, we are translating emerging disease biology into potential therapeutic opportunities, with the goal of providing meaningful new options for patients suffering from neurodegenerative diseases.”

About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Media

Susanne Kreuter 
VP Head of Strategic Marketing 
Susanne.Kreuter@evotec.com 

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com

Gerresheimer AG: Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year 

Duesseldorf, October 25, 2025. Today, Gerresheimer AG (ISIN: DE000A0LD6E6, “Gerresheimer”) obtained initial findings from an investigation by an external, independent law firm, which the company initiated, into the recognition of revenue and profits from bill-and-hold agreements in the 2024 financial year.

In September 2025, the German Federal Financial Supervisory Authority (BaFin) initiated an audit of the company’s disclosed consolidated financial statements and the associated group management report as of November 30, 2024. The audit focuses amongst others on orders for which so-called “bill-and-hold” agreements were concluded with the respective customers in the last third of the 2024 financial year. The audit is intended to clarify whether, based on these agreements, revenues were to be recognized in the consolidated financial statements for the 2024 financial year or in the 2025 financial year.

The revenues recognized in the 2024 financial year under bill-and-hold agreements total EUR 28 million. The Gerresheimer Group generated revenues of EUR 2.036 billion in the 2024 financial year.

After BaFin initiated its investigation, Gerresheimer AG commissioned an external, independent law firm to examine whether the requirements specified in the relevant accounting regulations for recognizing revenues from bill-and-hold agreements in the 2024 financial year had been met.

In the course of this independent investigation, the company has now become aware of new findings. Based on these findings, it is more likely to assume that, contrary to the previous opinion, the requirements for revenue recognition were not met for a contract with a volume of around EUR 3 million. Based on this finding, the company has decided to have the commissioned law firm fully review the underlying facts of the other bill-and-hold agreements concluded in the 2024 financial year as well.

The company will continue to cooperate fully with BaFin in the context of the ongoing audit to achieve complete and transparent clarification.

_______________________

Ende of inside information

Contact Gerresheimer AG

Investor Relations

Guido Pickert
Vice President Investor Relations

T +49 152 900 14145
gerresheimer.ir@gerresheimer.com

Media

Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264

jutta.lorberg@gerresheimer.com

Press release

Medios AG: Block placement of Bencis shares

Berlin, October 24, 2025 – The Medios-Group (“Medios“ or “the Company”), a leading provider of Specialty Pharma in Europe, was informed that Bencis Capital Partners B.V. (“Bencis”) has reallocated its entire shareholding in Medios AG. The shares, which represent a total of approx. 6.7% of Medios’ share capital, were sold to the institutional investor Janus Henderson Group Plc (“Janus Henderson”). The overall placement was advised by Berenberg.

The private equity investment company Bencis Capital Partners B.V. (Bencis) acquired 1,700,000 Medios shares in 2024 through a contribution-in-kind capital increase related to Medios’ acquisition of Ceban Pharmaceuticals B.V.

Matthias Gärtner, CEO of Medios AG, stated: “We welcome Janus Henderson as a new institutional and long-term-oriented investor among our shareholders and are pleased with the trust in our strategy and growth story. We have known Janus Henderson for many years and greatly appreciate the professional dialogue.”

About Medios AG

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the Company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Medios AG is Germany’s first listed specialty pharmaceutical Company. The shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.

www.medios.group

More information on individualized medicine: https://app.medios.group/en/individualizedmedicine

Contact

Claudia Nickolaus

Head of Investor & Public Relations, ESG Communications

Medios AG

Heidestraße 9 | 10557 Berlin

T +49 30 232 566 800

ir@medios.group

www.medios.ag

Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.

Relief Therapeutics Convenes Extraordinary General Meeting

GENEVA (Oct. 24, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has convened an extraordinary general meeting (EGM) to seek shareholder approval for the proposed business combination between Relief and NeuroX Group SA (NeuroX), as previously announced on October 8, 2025. The EGM will be held on November 14, 2025, at 5:30 p.m. CEST in Geneva, Switzerland.

AGENDA
Shareholders will be asked to approve several proposals, all contingent upon the completion of the proposed business combination.

These include an ordinary capital increase through the issuance of 140 million new ordinary shares, to be paid in by contribution in kind of NeuroX shares.

Shareholders will also vote on the election of new members to the board of directors, with four nominees — Walid Hanna, Olaf Blanke, Michael Stuenkel and Martin Reiss — proposed to join Relief’s board and succeed current directors who will step down. Gregory Van Beek, current vice-chairman, will continue to serve on the board to ensure continuity and oversee the integration of the two companies. In addition, shareholders will elect members of the nomination and compensation committee.

Further proposals include approval to rename the combined company MindMaze Therapeutics Holding SA, and to increase the capital band and conditional capital to levels commensurate with the post-transaction share capital.

The formal notice of convocation of the EGM, including information regarding attendance in person or by proxy, registration requirements, and ancillary documents, will be mailed to registered shareholders. The EGM comprehensive agenda and an investor presentation with additional information on the proposed combined company are available for download on Relief’s website.

ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.

ABOUT NEUROX
NeuroX is a Swiss-based, commercial-stage company that in 2025 acquired strategic assets of MindMaze Group SA and MindMaze SA (MindMaze), including intellectual property and the MindMaze^® brand.

MindMaze has developed first-of-its-kind neurotherapeutics that provide disease-modifying motor and cognitive treatments for neurological diseases and brain disorders. These neurotherapeutics are delivered through proprietary software and hardware, underpinned by an advanced brain technology platform that integrates wearables and sensors, and provides digital assessments as well as telehealth services. The unique suite of MindMaze solutions is delivered globally across the continuum-of-care, both in-clinic and in patients’ home, to successfully address some of neurology’s major unmet needs. NeuroX has already partnered with leading pharmaceutical companies that use its proprietary technology across multiple clinical trials.

Over the last decade, MindMaze has raised and invested more than USD 350 million to establish clinical evidence, demonstrate significant medico-economic outcomes, and market MindMaze’s disease-modifying therapeutic platform across neurological diseases, including stroke, Parkinson’s disease, and at-risk aging. In the United States, MindMaze has received a unique reimbursement code (CAT-3) to support the delivery of its home-based neurotherapeutic training. Its R&D pipeline focuses on adjacent neurological diseases, such as spinal cord injury, multiple sclerosis, traumatic brain injury, and Alzheimer’s disease/dementia.

Moved by the mission to accelerate the brain’s ability to recover, the MindMaze platform innovates by combining software-delivered behavioral treatments, drugs, devices, data, and AI to establish a new paradigm of precision medicine in neurology and neural repair.

CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. There can be no assurance that the proposed business combination will be completed on the terms described herein or at all. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Ad-hoc Disclosure of Inside Information Pursuant to Article 17 Regulation (EU)
No. 596/2014

Pentixapharm Focuses Development on Advanced Clinical Programs and Strengthens Financial Position by Discontinuing Preclinical Activities

Berlin, Germany, October 23, 2025 – The Managing Board and Supervisory Board of Pentixapharm Holding AG (Frankfurt Prime Standard: PTP, ISIN: DE000A40AEG0), an advanced clinical-stage biotech developing novel radiopharmaceuticals, today jointly resolved to significantly reduce early-stage research and development activities and concentrate resources on the company’s most advanced clinical programs.

This prioritization allows Pentixapharm to invest more effectively in its most value-generating development programs, including its Phase 3-ready CXCR4 flagship program aimed at improving the diagnosis of treatment-resistant hypertension. This decision represents a continuation of the clinical development strategy introduced in May 2025, which prioritizes high-value CXCR4-targeted programs.

The sharpened focus includes an adjustment of the organizational structure, accompanied by a targeted workforce reduction of approximately 50 % at Pentixapharm AG. Implementation is anticipated to be completed in the first half of 2026. The adjustments are expected to lower annual operating costs and extend the company’s cash runway through the first quarter of 2027.

About Pentixapharm

Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops precision diagnostics and therapeutics in oncology and cardiology to transform patient care. Its clinical pipeline is anchored by CXCR4-targeted PET-CT programs, including a Phase 3-ready candidate for the improved diagnosis of hypertensive patients with primary aldosteronism, which is intended to enable targeted treatment of the underlying causes of hypertension. CXCR4-based developments also include pioneering therapeutic programs in hematological cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. Complemented by CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain, Pentixapharm is poised to deliver meaningful patient benefit and sustainable growth in one of the fastest-growing areas of precision medicine.

Pentixapharm Investor and Media Contact

ir@pentixapharm.com

Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure

• Company focuses resources on its most advanced clinical development programs while reducing early-stage research activities
• Organizational adjustments include a workforce reduction of approximately 50 %, expected to lower operating costs and extend cash runway into Q1 2027
• Measures mark targeted continuation of the clinical development strategy outlined in May 2025

Berlin, Germany, October 23, 2025 – The Managing Board and Supervisory Board of Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, today jointly resolved to significantly reduce early-stage research and development activities and concentrate resources on the company’s most advanced clinical programs.

This prioritization allows Pentixapharm to invest more effectively in its most value-generating development programs, including the Phase 3-ready CXCR4 flagship program for the improved diagnosis of treatment-resistant hypertension. This decision represents a continuation of the clinical development strategy introduced in May 2025, which prioritizes high-value CXCR4-targeted programs.

The sharpened focus includes an adjustment of the organizational structure, accompanied by a targeted workforce reduction of approximately 50 % at Pentixapharm AG. Implementation is anticipated to be completed in the first quarter of 2026. The adjustments are expected to lower annual operating costs and extend the company’s cash runway through the first quarter of 2027.

“Our Phase 3-ready PentixaFor CXCR4 program for the diagnosis of treatment-resistant hypertension has made significant progress in recent months and remains a central value driver, showcasing Pentixapharm’s clinical development expertise,” said Dr. Dirk Pleimes, CEO and CMO of Pentixapharm AG. “Optimizing our operational costs is an important step to enhance the company’s efficiency and lay a solid foundation for achieving the next clinical milestones. While the adjustment of our organizational structure was a carefully considered decision, it is essential to safeguard the company’s long-term value and support sustainable growth. We will implement the measures responsibly and support to our employees throughout the transition period.”

About Pentixapharm

Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops precision diagnostics and therapeutics in oncology and cardiology to transform patient care. Its clinical pipeline is anchored by CXCR4-targeted PET-CT programs, including a Phase 3-ready candidate for the improved diagnosis of hypertensive patients with primary aldosteronism, which is intended to enable targeted treatment of the underlying causes of hypertension. CXCR4-based developments also include pioneering therapeutic programs in hematological cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. Complemented by CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain, Pentixapharm is poised to deliver meaningful patient benefit and sustainable growth in one of the fastest-growing areas of precision medicine.

Pentixapharm Investor and Media Contact

ir@pentixapharm.com

Secarna Pharmaceuticals enters discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target

• The companies will jointly develop a first-in-class disease-modifying oligonucleotide against a newly validated target relevant for rare genetic disorders as well as broader disease conditions
• Collaboration will leverage expertise and synergies of both companies’ platforms to bring new treatments to patients

Martinsried (Munich), Germany, October 23, 2025 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the signing of an agreement with Scenic Biotech B.V., a pioneer in modifier therapies for severe genetic diseases. The agreement covers the discovery and co-development of oligonucleotides against a novel target identified and validated by Scenic Biotech’s proprietary Cell-Seq platform.

Secarna will lead the oligonucleotide discovery part of the collaboration, bringing OligoCreator^®, its proprietary AI-empowered oligonucleotide discovery and development platform, to the co-development. OligoCreator^® has been shown to greatly expedite the drug discovery process, from target selection to therapeutic development, identifying and characterizing potentially safe and efficacious therapeutic candidates at unparalleled speed. Within the collaboration, Secarna will utilize its platform to identify promising candidates, while Scenic will add its expertise on target and disease biology.  

“We are really excited to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases. We were drawn together because both companies are working to tackle challenging-to-treat diseases in new ways, and we saw much synergy between our technologies and experience,” said Konstantin Petropoulos, PhD, CEO of Secarna Pharmaceuticals. “From selecting the best target with the input of Scenic’s Cell-Seq platform to discovering the best oligonucleotide therapeutic candidates with Secarna’s OligoCreator® technology, we look forward to breaking new ground to jointly develop novel treatment options for patients in need.”

About Secarna Pharmaceuticals

Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and development of best-in-class oligonucleotide therapeutics, offering hope to patients facing conditions that are beyond the reach of current approaches and modalities. With the Company’s proprietary AI-empowered OligoCreator® platform, which includes multiple delivery technologies, Secarna identifies and characterizes oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By delivering these novel therapeutics to the cells, organs, or tissues where they are needed, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Secarna’s unique OligoCreator® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine. www.secarna.com

Contact
Secarna Pharmaceuticals GmbH & Co. KG
Konstantin Petropoulos, PhD, MBA
CEO
Phone: +49 (0)89 215 46 375
Email: info@secarna.com

For media inquiries
MC Services AG
Anne Hennecke/Lydia Robinson-Garcia
Phone: +49 (0)211 52 92 52 15
Email: secarna@mc-services.eu

PRESS RELEASE

Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025

• Withdrawal of the convocation request as of 1 August 2025 by Grifols S.A.

Dreieich, 23 October 2025. Biotest AG hereby announces that its majority shareholder, Grifols S.A., Barcelona, Spain, informed the Management Board on 22 October 2025 that it is withdrawing from the request as of 1 August 2025 to convene an extraordinary general meeting. In the same letter, Grifols S.A. also requested the convening of an extraordinary general meeting to resolve on the change of legal form of Biotest AG from a stock corporation (Aktiengesellschaft, AG) into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA). The Supervisory Board was immediately informed of the receipt of this request.

The Management Board with the approval of the Supervisory Board decided to cancel the extraordinary general meeting scheduled for 28 October 2025.

The Management Board will carefully review the new request of Grifols S.A. to convene an extraordinary general meeting to resolve on the change of legal form of the company into a partnership limited by shares (KGaA), pursuant to Section 122 (1) of the German Stock Corporation Act (AktG). If the new request for convocation is admissible, the Management Board will invite again to an extraordinary general meeting. The details will be published by the company.

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,500 employees worldwide. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Baumann (Buttkereit)

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Miriam Oehme

Phone: +49 -152 07016 992
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

PRESS RELEASE

Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma

• Recognizes the potential of HDP-101 to address a serious or life-threatening condition with high unmet medical needs
• Enables more frequent engagement with FDA and eligibility for rolling review to support expedited development and review

Ladenburg, Germany, 23 October 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that HDP-101 (INN: pamlectabart tismanitin), the Company’s lead Amanitin-based ADC candidate, has been granted Fast Track Designation by the US Food and Drug Administration (FDA).

This designation was supported by nonclinical data as well as clinical data from the ongoing Phase I/IIa study with HDP-101 (INN: pamlectabart tismanitin), evaluating the safety and antitumor activity of the candidate in patients with relapsed or refractory multiple myeloma.

Professor Andreas Pahl, Chief Executive Officer of Heidelberg Pharma, commented: “The FDA’s granting of Fast Track Designation is fantastic news for Heidelberg Pharma and underscores the potential of HDP-101 for the treatment of severely ill and heavily pretreated patients. This designation will support our efforts to advance our lead ADC candidate efficiently toward patients with multiple myeloma who continue to face significant unmet medical needs.”

Fast Track Designation is intended to accelerate the development and review of therapies that address serious or life-threatening conditions with unmet medical needs. This status enables more frequent engagement with the FDA, allows Rolling Review of the Biologics License Application (BLA), and may provide eligibility for Priority Review or Accelerated Approval.

HDP-101 (INN: pamlectabart tismanitin) is an investigational product that has not yet received marketing approval by any regulatory authority, including the FDA. The safety and efficacy of this investigational compound is currently being evaluated and is not yet established.

About Heidelberg Pharma

Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.

Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology.

The lead candidate HDP-101 is a BCMA ATAC in clinical development for multiple myeloma. A second ATAC candidate, HDP-102, has recently started clinical development in Non-Hodgkin Lymphoma and is currently on a temporary hold. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. Heidelberg Pharma is open for partnering.

The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com

ATAC^® is a registered trademark of Heidelberg Pharma Research GmbH.

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

• SYNLAB strengthens its commitment to care excellence in Italy by pioneering the installation of a photon-counting CT scanner at its Naples medical and research centre; this is one of the first systems of its kind available in Europe, offering the most advanced imaging technology today.
• The new scanner enhances patient comfort and supports healthcare professionals with, faster, safer and more accurate diagnostics.

SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, has reinforced its commitment to care excellence in Italy by pioneering the installation of a photon-counting CT scanner at its medical and research centre in Naples. This investment reflects the Group’s strategy of delivering best-in-class care excellence across its network.

Photon-counting CT marks one of the most significant advances in radiology in over a decade, offering next-generation imaging capabilities that transform both clinical outcomes and patient experience. Unlike conventional CT systems, it directly detects individual X-ray photons, enabling ultra-high-resolution imaging with markedly reduced radiation exposure and faster scan times. Integrated with advanced artificial intelligence, the new photon-counting CT scanner leverages deep learning algorithms to further enhance image quality, accelerate reporting, and support more accurate diagnostics.

This breakthrough technology allows clinicians to visualise anatomical structures with microscopic precision, supporting earlier and more accurate diagnoses in cardiovascular, neurological and oncological care and is particularly effective for complex cases such as coronary disease, tumour staging, and high-resolution lung studies. Designed with patient comfort in mind, the new scanner facilitates more streamlined procedures while equipping healthcare professionals with sharper, more actionable insights for timely and accurate decision-making.

SYNLAB Italy has invested over €9 million in advanced imaging diagnostics in 2024 and 2025, delivering more than 300,000 procedures this year alone.

This latest investment adds to SYNLAB’s recent opening of the SYNLAB Manifattura Firenze Medical Centre in Florence and follows a series of strategic acquisitions in the country. Together, these developments demonstrate SYNLAB’s long-term commitment to Italy and its ambition to be the diagnostic partner of choice for both patients and healthcare professionals.

“Our focus is on creating environments where patients feel safe, supported and well cared for,” said Iris Faull, Chief Medical Officer at SYNLAB Group. “At the same time, we are equipping healthcare professionals across disciplines with the most advanced tools available to deliver precise, efficient and high-quality diagnostics.”

Installing the photon-counting CT scanner in Naples is a significant step forward in offering innovative diagnostic solutions tailored to the needs of patients and healthcare professionals alike.

– Ends –

For more information:

About SYNLAB

• SYNLAB Group is a leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments, and corporates.
• Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
• SYNLAB operates in more than 20 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 24,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.
• SYNLAB performed around 600 million laboratory tests and achieved revenues of €2.62 billion in 2024.
• More information can be found on www.synlab.com